Replies to post #9683 on Ariad Pharmaceuticals Inc fka ARIA

[DonShimoda]

BRAF mutations are my top choice as well. Sorafenib failed to improve survival precisely because it did not target the mutated form of BRAF present in about 60% of malignant melanomas. In addition to 60% of melanomas, BRAF mutations are found in almost half of thyroid cancers and in about 10 to 15% of ovarian and colorectal cancers. I don't know if this is something Ariad is working on but targeting BRAF mutations clearly represents a huge opportunity.